Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167429 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL3332188 | 0.86 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2CYP1A2KDM4EMAPT | |
| SCHEMBL2904899 | 0.85 | EGFR (0.46) | KMT2A | |
| SCHEMBL3336367 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL30002312 | 0.82 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL1733527 | 0.82 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL3330035 | 0.81 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL164778 | 0.81 | KMT2A (0.50) | SMN1; SMN2ALOX15KDM4EMAPTADORA2A | |
| SCHEMBL3331633 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2CYP1A2KDM4EHPGD | |
| SCHEMBL4470516 | 0.81 | KDM4E (0.46) | ALDH1A1SMN1; SMN2CYP1A2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870633-B2 | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | Szegedi Tudományegyetem (HU) | 2020-12-22 | — | — | US | disclosed |
| EP-3423444-B1 | NOVEL TYPES OF C-3 SUBSTITUTED KINURENIC ACID DERIVATIVES WITH IMPROVED NEUROPROTECTIVE ACTIVITY | UNIV SZEGEDI (HU) | 2020-11-18 | — | — | EP | disclosed |
| US-20190106409-A1 | NOVEL TYPES OF C-3 SUBSTITUTED KYNURENIC ACID DERIVATIVES WITH IMPROVED NEUROPROTECTIVE ACTIVITY | Szegedi Tudományegyetem (HU) | 2019-04-11 | — | — | US | disclosed |
| EP-3423444-A1 | NOVEL TYPES OF C-3 SUBSTITUTED KINURENIC ACID DERIVATIVES WITH IMPROVED NEUROPROTECTIVE ACTIVITY | Szegedi Tudományegyetem (HU) | 2019-01-09 | — | — | EP | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | ALDH1A1 2297/4885SMN1; SMN2 4406/4885GABRA2 639/4885 |
| US-20190106409-A1 | NOVEL TYPES OF C-3 SUBSTITUTED KYNURENIC ACID DERIVATIVES WITH IMPROVED NEUROPROTECTIVE ACTIVITY | KYNU, KMO, PARK7 | ALDH1A1 2827/4885SMN1; SMN2 439/4885GABRA2 590/4885 |
| US-10870633-B2 | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | KYNU, KMO, PARK7 | ALDH1A1 2924/4885SMN1; SMN2 527/4885GABRA2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.